Notable Labs, Ltd.
Healthcare · Pharmaceutical Preparations · L3 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | |
|---|---|---|---|
| Revenue | $310,000 | $8,000 | $768,000 |
| Operating income | −$14.7M | −$12.9M | −$30.0M |
| Net income | −$11.3M | −$14.4M | −$29.9M |
| Total assets | $19.5M | $5.5M | $64.7M |
| Total liabilities | $4.4M | $7.1M | $12.5M |
| Equity | $15.1M | −$37.0M | −$53.9M |
| EPS (diluted) | $-3.41 | $-21.97 | $0.45 |
| Shares out. | 69.8M | 970,192 | 68.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −4728.1%
- Net margin
- −3633.5%
- Return on equity
- −74.5%
- Return on assets
- −57.6%
- Return on capital (ROCE)
- −87.2%
- Liabilities / assets
- 22.7%
- Debt / equity
- 0.29×
- Book value / share
- $0.22
- Revenue growth (YoY)
- 3775.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -10.91distress
- Accruals / assets
- 12.5%high accruals
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeOct 16, 2024
- Bankruptcy or receivership · Director / officer changeOct 15, 2024
- Costs from exit or disposalSep 19, 2024
- Director / officer changeSep 16, 2024
- Director / officer change · Regulation FD disclosureAug 26, 2024
- Regulation FD disclosureAug 6, 2024
- Other material eventJul 24, 2024
- Delisting / listing-standard noticeJul 19, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SEC STAFF ACTIONAug 18, 2025
- 25-NSEMar 5, 2025
- 8-KOct 16, 2024
- 8-KOct 15, 2024
- 3INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESSep 26, 2024
- 8-KSep 19, 2024
- 8-KSep 16, 2024
- S-1/AAug 29, 2024
- S-1/AAug 26, 2024
- 8-KAug 26, 2024
- 10-QAug 14, 2024
- SC 13D/AAug 9, 2024
- 8-KAug 6, 2024
- 8-KJul 24, 2024
- 8-KJul 19, 2024